Santé log

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix

The joint venture between IBA and Framatome will leverage Telix’s capabilities to accelerate the production and availability of Astatine-211 in the US market.
Santé log

JJP Biologics Doses the First Patients in Phase 1b Clinical Trial of Nebaprubart in Rheumatoid Arthritis (RA)

Expansion of nebaprubart (JJP-1212) into RA follows positive interim data from its ongoing Phase 1b trial in linear IgA dermatosis (LAD), marking the second indication for the Company’s lead asset and ...
Santé log

IBA launches NEPTIS® Perform Duo, one synthesizer module from tracer development to routine production

Developing a new PET imaging agent, known as a tracer, takes many trial runs. On most synthesizers, each run uses a new single-use kit. As a result, producers that both develop and manufacture tracers ...
Santé log

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Building on convincing two-year results In addition to promising response rates, the two-year data from the trial also showed a durable clinical benefit, with 92% of patients still responding at two ...
Santé log

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

Precision Medicine Approach in a Large Market: Licaminlimab is positioned as a potential first-in-class precision medicine for an estimated 1.5+ million patients in the U.S. with moderate-to-severe ...
Santé log

Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO

Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from ...
Santé log

RAMSAY GENERALE DE SANTE : Availability of the 2026 URD - Evolution in the Governance - Annual General meeting on 4th December 2026

The appointment of Mr Pascal Roché, the Company’s Chief Executive Officer, and Ms Alexandra Boleslawski as Directors will also be proposed to the General Meeting of 4 December 2026. These appointments ...
Santé log

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical ...
Santé log

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

Zealand Pharma initiated a Phase 1b trial with efficacy endpoints, investigating ZP9830 in people with plaque psoriasis. The trial was initiated on the back of positive topline results from the single ...
Santé log

OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

The primary endpoint was met and results showed a statistically significant 1-year OS rate for both combinations of Tedopi® and docetaxel (OS = 47%; p = 0.001) and Tedopi® and nivolumab (OS = 46%; p = ...
Santé log

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company advancing targeted theranostics to improve outcomes for people with cancer across the patient ...
Santé log

Intelligent Scopes Unveils the ISC 100: The Solution Enabling Urology AI to Work Beside Any Cystoscopy Tower — No Replacement, No Rewiring, No Cloud

CystoSmart running on the ISC 100: Urology Al that works beside any cystoscopy tower ...